Skip to main content
. 2014 May 29;9(5):e97719. doi: 10.1371/journal.pone.0097719

Figure 4. Decitabine and gefitinib combination therapy alters the expression levels of apoptotic regulatory factors.

Figure 4

SW1116 and LOVO cells were plated, treated for 48(DAC) and gefitinib (GEF) either alone or in combination. (A) and (B) the expression levels of cleaved-caspase 3, cleaved-PARP, XAF1, XIAP, BAX, Bcl-2 were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments. (C) and (D) The caspase 3 activity was quantified as described under methods. This experiment was repeated thrice. Columns, mean; bars, SD. *, P<0.05; **, P<0.01; ***, P<0.001. (E) and (F) The caspase 8 activity was quantified as described under Methods. This experiment was repeated thrice. Columns, mean; bars, SD. *, P<0.05; **, P<0.01; ***, P<0.001.